Drug maker Unichem Laboratories today said it has received approval from the US health regulator to market Valsartan tablets, a hypertension drug.
The company has received approval from the US Food and Drug Administration (USFDA) to market the product, Unichem Laboratories said in a regulatory filing.
The company's product is the generic version of Novartis Pharmaceuticals Corp's Diovanb tablets and is indicated for lowering the blood pressure.
The product will be commercialised from the company's Ghaziabad plant, it added.
Shares of Unichem Laboratories today ended 0.23 down at Rs 279.30 on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)